Corcept Therapeutics moves forward with a groundbreaking advertising campaign to increase awareness of Cushing’s by focusing on the results of recent research conducted by the company that shows that almost 25% of people with difficult-to-treat Type-2 diabetes may, in fact, have Cushing’s Syndrome, which could, also be the underlying cause of the diabetes.
The CATALYST study enrolled 1,055 patients across 36 sites in the U.S., making it the most extensive and rigorous study ever conducted to assess the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes. Of the patients enrolled in CATALYST, 24 percent were identified as having hypercortisolism. Corcept president of Endocrinology, Sean Maduck, said this emerging research and this new campaign, Corcept, is focused on increasing the awareness of endogenous hypercortisolism and decreasing the time patients may languish without a proper diagnosis.
“Until now, hypercortisolism has been widely regarded as extremely rare. But that turns out not to be true. These results show that hypercortisolism among patients with difficult-to-control type 2 diabetes is much more common than previously assumed and is likely the underlying cause of diabetes in many cases,” said Ralph DeFronzo, MD, chief of the Diabetes Division and professor of medicine at UT Health San Antonio and CATALYST study investigator.
To learn more, visit Cortisol in Control
Here is more information on the CATALYST study
If you want to learn more about Cushing’s buy Dr. Blevins book and check out Pituitary World News’ extensive coverage of the disease.
© 2025, Pituitary World News. All rights reserved.